Company news
Travere Therapeutics, Inc. news in 2025
Travere Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
November 5, 2025
Travere Therapeutics to Participate at Upcoming Investor Conferences
November 3, 2025
Travere Therapeutics Reports Third Quarter 2025 Financial Results
October 29, 2025
Travere Therapeutics to Report Third Quarter 2025 Financial Results
October 22, 2025
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
October 16, 2025
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
September 25, 2025
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
September 9, 2025
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
September 2, 2025
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
August 26, 2025
Travere Therapeutics Reports Second Quarter 2025 Financial Results
August 6, 2025
Travere Therapeutics to Report Second Quarter 2025 Financial Results
July 29, 2025
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
June 10, 2025
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
June 9, 2025
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
June 2, 2025
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
May 22, 2025
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
May 14, 2025
Travere Therapeutics Reports First Quarter 2025 Financial Results
April 30, 2025
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
April 28, 2025
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
April 28, 2025
Travere Therapeutics to Report First Quarter 2025 Financial Results
April 23, 2025
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
March 30, 2025
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
March 16, 2025
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 19, 2025
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 12, 2025
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
February 10, 2025
Travere Therapeutics Provides Corporate Update and 2025 Outlook
January 12, 2025
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 5, 2025
Calls in 2025
- Travere Therapeutics (NASDAQ:TVTX) Q3 2025 Earnings Call
Oct 30, 2025
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q2 2025 Earnings Call
Aug 6, 2025
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q1 2025 Earnings Call
May 1, 2025
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q4 2024 Earnings Call
Feb 20, 2025
Transcript
Decks in 2025
- Technical Presentation (June 2025)
Technical · 11 slides · June 2025
- ERA Congress 2025 (Vienna & Virtual, June 4-7, 2025)
Conference · 11 slides · June 2025
- Technical Presentation (June 2025)
Technical · 16 slides · June 2025
- Technical Presentation (May 2025)
Technical · 29 slides · May 2025